This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

October 20, 2025

Study Completion Date

October 20, 2025

Conditions
Neoplasms
Interventions
DRUG

BI 907828

Film-coated tablet

Trial Locations (27)

1200

Cliniques Universitaires Saint-Luc, Brussels

2100

Rigshospitalet, København, København Ø

3000

UZ Leuven, Leuven

10065

Memorial Sloan-Kettering Cancer Center, New York

13125

Helios Klinikum Berlin-Buch, Berlin

15706

Hospital Clínico de Santiago, Santiago de Compostela

28040

Fundación Jiménez Díaz, Madrid

34232

Florida Cancer Specialists-Sarasota-61670, Sarasota

37075

Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen

37203

SCRI Oncology Partners, Nashville

40202

Norton Cancer Institute, Downtown, Louisville

49546

START Midwest, Grand Rapids

50937

Universitätsklinikum Köln (AöR), Cologne

53792

University of Wisconsin, Madison

72076

Universitätsklinikum Tübingen, Tübingen

77030

The University of Texas MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Center, Santa Monica

6423906

Sourasky Medical Center, Tel Aviv

06511

Yale University School of Medicine, New Haven

K1H 8L6

The Ottawa Hospital, Ottawa

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

60-693

MED POLONIA SP Z O O, Clinical Trials Department,Poznan, Poznan

02-781

Oncology Center-Maria Sklodowska-Curie Institute, Warsaw

03722

Severance Hospital, Seoul

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

171 76

Karolinska Comprehensive Cancer Center, Stockholm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY